Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.46 - $14.53
Previous CloseN/A
Volume95.69K
Average Volume (3M)231.72K
Market Cap
$276.02M
Enterprise Value$273.37M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 06, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding39,487,880
10 Day Avg. Volume237,723
30 Day Avg. Volume231,721
Standard Deviation0.17
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.48
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda-5.35
Forecast
1Y Price Target
$11.67Price Target Upside75.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Pulmonx News
PremiumCompany Announcements
Pulmonx Corporation’s Earnings Call Reveals Strong Growth and Challenges
PremiumCompany Announcements
Pulmonx Corporation Achieves Record Revenue Growth in 2024
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePulmonx reported Q3 revenue of $20.4M, ahead of our $19.5M estimate and consensus of $20.3M.
Market OpportunityPulmonx is a high-quality MedTech growth story with proven technology solving an unmet need in a $10B+ WW market opportunity.
Product And Market PenetrationThe Zephyr Valves are considered the standard of care in a significantly underpenetrated market with a total addressable market of $12 billion worldwide.
Bears Say
Management TurnoverDespite management turnover and broader MedTech weakness, the current team has been executing effectively to numbers.
Regulatory ChallengesAeriseal is CE marked in Europe and is under investigation for US approval, with expected launches in the EU in 2026 and the US in 2027.
Safety ConcernsThe overall safety profile appears manageable, with a pneumothorax rate improving from 29% to 23.7%.
---
Ownership Overview
10.78% Insiders
35.93% Mutual Funds
32.41% Other Institutional Investors
5.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $5.46 and its highest was $14.53 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $276.02M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is May 06, 2025 which is in 74 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Feb 19, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.447 by $0.117.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.39.
How many shares outstanding does Pulmonx have?
Pulmonx has 39,487,880 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.447. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
---
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.67 (75.75% Upside)
$11.67 (75.75% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.63%
12-Months-Change
Fundamentals
Return on Equity
-51.99%
Trailing 12-Months
Asset Growth
-9.52%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Pulmonx demonstrated strong revenue growth and international expansion, with significant advancements in clinical trials and product innovation. However, increased operating expenses and persistent net losses highlight ongoing financial challenges. The future outlook includes strategic initiatives to sustain growth, but foreign exchange fluctuations pose a potential risk.Read More>---
LUNG Stock 12 Month Forecast
Average Price Target
$11.67
▲(75.75% Upside)
Technical Analysis
Insulet
―
NovoCure
―
Irhythm Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-27.98%
reiterated a buy rating yesterday
Copying Jason Bednar's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -27.98% per trade.
---